A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
A prospective multicenter study comparing patients with CRVO amd secondary macular edema
treated with ranibizumab versus sham. Safety and efficacy will be evaluated. Patients will be
randomized in a 1:1 ratio to one of the two arms. 32 patients, 6 months follow up. There will
be monthly visits with injection the first three months and subsequently new injection if
present edema.